Activating mutations in BRAF (e.g., V600E) drive tumor proliferation, making BRAF inhibitors like vemurafenib and dabrafenib cornerstone therapies (Dankner et al., 2018; Chapman et al., 2025). The gene discussed is BRAF; the disease is neoplasm.